Jun-Goo Kwak

Matthew Kaplan

William Wood

Matthew Cowper

Mayank Mamtani

Thomas Smith

Medicine Azad

Nat Charoensook

Yasmeen Rahimi

- Immunic, Inc. presented positive Phase 2 CALLIPER trial data for its lead asset, **vidofludimus calcium (IMU-838)**, in Progressive Multiple Sclerosis (PMS) at the 41st Congress of ECTRIMS on **September 25, 2025**.  **[1280776_0001193805-25-001357_e664856_ex99-1.htm:0]** 
- The data demonstrated **statistically significant 24-week confirmed disability improvement (24wCDI)** with an over two-fold probability over placebo in the overall PMS study population.  **[1280776_0001193805-25-001357_e664856_ex99-1.htm:0]** 
- In the overall PMS population, vidofludimus calcium reduced the risk of 24-week confirmed disability worsening (24wCDW) by **23.8%** versus placebo.  **[1280776_0001193805-25-001357_e664856_ex99-1.htm:1]** 
- Long-term data from the Phase 2 EMPhASIS trial in Relapsing-Remitting Multiple Sclerosis (RRMS) showed favorable safety and tolerability, with **92.7% of patients remaining free of 24wCDW at week 144**.  **[1280776_0001193805-25-001357_e664856_ex99-1.htm:0]** **[1280776_0001193805-25-001357_e664856_ex99-1.htm:2]** 
- Top-line data for the fully enrolled twin Phase 3 ENSURE trials in relapsing multiple sclerosis (RMS) is **expected by the end of 2026**.  **[1280776_0001193805-25-001357_e664856_ex99-1.htm:1]** **[1280776_0001193805-25-001357_e664856_ex99-1.htm:3]**

Immunic Presents Positive Vidofludimus Calcium Data at ECTRIMS

- Immunic presented **positive Phase 2 CALLIPER trial data** for vidofludimus calcium in Progressive Multiple Sclerosis (PMS) at the 41st Congress of ECTRIMS, demonstrating statistically significant 24-week Confirmed Disability Improvement (24wCDI) and a **23.8% reduction** in the risk of 24-week Confirmed Disability Worsening (24wCDW) versus placebo in the overall PMS population.  **[1280776_20250925NY83195:0]** **[1280776_20250925NY83195:1]** 
- The CALLIPER findings support vidofludimus calcium's **neuroprotective potential** and its promise to slow disease progression, with evidence of clinical activity meriting further investigation in a potential Phase 3 program.  **[1280776_20250925NY83195:0]** **[1280776_20250925NY83195:1]** 
- Long-term data from the Phase 2 EMPhASIS trial in Relapsing-Remitting Multiple Sclerosis (RRMS) demonstrated **robust efficacy signals** and a **favorable long-term safety and tolerability profile**, with **92.7%** of patients remaining free of 24-week Confirmed Disability Worsening at week 144.  **[1280776_20250925NY83195:0]** **[1280776_20250925NY83195:2]** 
- Top-line data for Immunic's fully enrolled twin Phase 3 ENSURE trials in Relapsing Multiple Sclerosis (RMS) is expected by the **end of 2026**.  **[1280776_20250925NY83195:1]** **[1280776_20250925NY83195:3]**

Immunic Presents Positive Clinical Data for Vidofludimus Calcium in Multiple Sclerosis

IMMUNIC (IMUX)